SPRY

SEC source: 0001209191-23-028507 · doc4.xml · derivative · entry 6

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 345,897

Underlying: Common Stock · 57,100 shares

Expires 2030-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-028507 · doc4.xml · nonDerivative · entry 3

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 210,346

F3 · kind: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $6.00 to $6.44, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.

SEC source: 0001209191-23-028507 · doc4.xml · nonDerivative · entry 2

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 267,446

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-001926 · doc4.xml · derivative · entry 1

Dorsey Brian · CIK 0001380762 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,000

Underlying: Common Stock · 145,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-001933 · doc4.xml · derivative · entry 1

Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-001931 · doc4.xml · derivative · entry 1

Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on December 1, 2023, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-001929 · doc4.xml · derivative · entry 1

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,000

Underlying: Common Stock · 165,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-001928 · doc4.xml · derivative · entry 1

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-001927 · doc4.xml · derivative · entry 2

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 1,100,000

Underlying: Common Stock · 1,100,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-001927 · doc4.xml · derivative · entry 1

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-001924 · doc4.xml · derivative · entry 2

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-001924 · doc4.xml · derivative · entry 1

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,100,000

Underlying: Common Stock · 1,100,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-22-059187 · doc4.xml · nonDerivative · entry 1

Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 8,250

F1 · price: The price reported in Column 4 is the weighted average price. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.26, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2 · ownership.nature: By Scott 2008 Trust Dated 3/28/08.

SEC source: 0001209191-23-028507 · doc4.xml · nonDerivative · entry 1

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 210,346

F1 · shares: Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $4.53 to $5.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.

SEC source: 0001209191-22-056447 · doc4.xml · derivative · entry 5

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,733

Underlying: Common Stock · 82,733 shares

Expires 2031-12-14

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F6 · price: Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement.

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056447 · doc4.xml · derivative · entry 4

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,260

Underlying: Common Stock · 48,260 shares

Expires 2029-12-17

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F5 · price: Received in exchange for a stock option to acquire 40,833 shares of common stock of ARS with the exercise price of $0.99 per share pursuant to the Merger Agreement.

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056447 · doc4.xml · derivative · entry 3

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,380

Underlying: Common Stock · 236,380 shares

Expires 2029-07-05

F3 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS under the Merger Agreement.

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

SEC source: 0001209191-22-056447 · doc4.xml · derivative · entry 2

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,380

Underlying: Common Stock · 236,380 shares

Expires 2029-07-05

F3 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS under the Merger Agreement.

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056447 · doc4.xml · nonDerivative · entry 1

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,380

F1 · price: Received in exchange for 200,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

SEC source: 0001209191-22-056445 · doc4.xml · derivative · entry 2

Shah Pratik · CIK 0001580787 · Director · 10% owner

Pratik Shah Living Trust dated June 15, 2011 · CIK 0001953388 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 354,570

Underlying: Common Stock · 354,570 shares

Expires 2031-11-30

F4 · price: Received in exchange for a stock option to acquire 300,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement.

F5 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F3 · derivative.exercise_date: The shares subject to the option vest in a series of thirty-six (36) equal monthly installments measured from the vesting commencement date.

SEC source: 0001209191-22-056445 · doc4.xml · nonDerivative · entry 1

Shah Pratik · CIK 0001580787 · Director · 10% owner

Pratik Shah Living Trust dated June 15, 2011 · CIK 0001953388 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By The Pratik Shah Living Trust dated June 15, 2011

Disclosed balance after: 10,156,204

F1 · price: Received in exchange for 8,593,116 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F2 · ownership.nature: These shares are held in a trust for the benefit of the Reporting Person. The Reporting Person is trustee of the trust.

SEC source: 0001209191-22-056446 · doc4.xml · derivative · entry 1

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 614,588

Underlying: Common Stock · 614,588 shares

Expires 2032-05-24

F2 · price: Received in exchange for a stock option to acquire 520,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $1.77 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056444 · doc4.xml · derivative · entry 2

SCHNEIDER PHILLIP M · CIK 0001230051 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,823

Underlying: Common Stock · 76,823 shares

Expires 2031-12-14

F3 · price: Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F5 · price: Received in exchange for a stock option to acquire 65,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement.

F4 · derivative.exercise_date: The shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments measured from the vesting commencement date.

SEC source: 0001209191-22-056444 · doc4.xml · derivative · entry 1

SCHNEIDER PHILLIP M · CIK 0001230051 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,647

Underlying: Common Stock · 153,647 shares

Expires 2029-07-05

F2 · price: Received in exchange for a stock option to acquire 130,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $0.99 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement").

F3 · price: Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001104659-22-117290 · tm2230267-2_4.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 902,904

F3 · price: Received in exchange for 763,942 shares of common stock of ARS pursuant to the Merger Agreement. Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F4 · balance_after: These shares are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").

F4 · ownership.nature: These shares are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").

F5 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-117290 · tm2230267-2_4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,106,774

F1 · price: Received in exchange for 1,782,531 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F2 · balance_after: These shares are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: These shares are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F5 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001209191-22-056443 · doc4.xml · derivative · entry 8

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 236,380

Underlying: Common Stock · 236,380 shares

Expires 2031-12-13

F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F11 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS with an exercise price of $1.70 per share pursuant to the Merger Agreement.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056443 · doc4.xml · derivative · entry 7

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 236,380

Underlying: Common Stock · 236,380 shares

Expires 2029-12-16

F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F10 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS with an exercise price of $0.99 per share pursuant to the Merger Agreement.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056443 · doc4.xml · derivative · entry 6

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,733

Underlying: Common Stock · 82,733 shares

Expires 2031-12-13

F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F9 · price: Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056443 · doc4.xml · derivative · entry 5

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,733

Underlying: Common Stock · 82,733 shares

Expires 2029-12-16

F7 · price: Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with the exercise price of $0.99 per share pursuant to the Merger Agreement.

F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056443 · doc4.xml · nonDerivative · entry 4

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 4,326,854

F5 · price: Received in exchange for 3,660,930 shares of common stock of ARS pursuant to the Merger Agreement.

SEC source: 0001209191-22-056443 · doc4.xml · nonDerivative · entry 3

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Richard Lowenthal Charitable Remainder Unitrust Dated January 7, 2020

Disclosed balance after: 1,772,850

F2 · price: Received in exchange for 1,500,000 shares of common stock of ARS pursuant to the Merger Agreement.

F4 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001209191-22-056443 · doc4.xml · nonDerivative · entry 2

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder Unitrust Dated January 7, 2020

Disclosed balance after: 1,772,850

F2 · price: Received in exchange for 1,500,000 shares of common stock of ARS pursuant to the Merger Agreement.

F3 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001209191-22-056443 · doc4.xml · nonDerivative · entry 1

Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,326,854

F1 · price: Received in exchange for 3,660,930 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

SEC source: 0001209191-22-056442 · doc4.xml · derivative · entry 8

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 82,733

Underlying: Common Stock · 82,733 shares

Expires 2031-12-13

F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F11 · price: Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with an exercise price of $1.70 per share pursuant to the Merger Agreement.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056442 · doc4.xml · derivative · entry 7

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 82,733

Underlying: Common Stock · 82,733 shares

Expires 2029-12-16

F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F10 · price: Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with an exercise price of $0.99 per share pursuant to the Merger Agreement.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056442 · doc4.xml · derivative · entry 6

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,380

Underlying: Common Stock · 236,380 shares

Expires 2031-12-13

F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F9 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS with an exercise price of $1.70 per share pursuant to the Merger Agreement.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056442 · doc4.xml · derivative · entry 5

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,380

Underlying: Common Stock · 236,380 shares

Expires 2029-12-16

F7 · price: Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS with an exercise price of $0.99 per share pursuant to the Merger Agreement.

F8 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056442 · doc4.xml · nonDerivative · entry 4

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder Unitrust Dated January 7, 2020

Disclosed balance after: 1,772,850

F2 · price: Received in exchange for 1,500,000 shares of common stock of ARS pursuant to the Merger Agreement.

F5 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001209191-22-056442 · doc4.xml · nonDerivative · entry 3

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 4,326,854

F4 · price: Received in exchange for 3,660,930 shares of common stock of ARS pursuant to the Merger Agreement.

SEC source: 0001209191-22-056442 · doc4.xml · nonDerivative · entry 2

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder Unitrust Dated January 7, 2020

Disclosed balance after: 1,772,850

F2 · price: Received in exchange for 1,500,000 shares of common stock of ARS pursuant to the Merger Agreement.

F3 · ownership.nature: The Reporting Person is trustee of the trust.

SEC source: 0001209191-22-056442 · doc4.xml · nonDerivative · entry 1

Lowenthal Richard E · CIK 0001378550 · Director · President and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,176,822

F1 · price: Received in exchange for 4,380,084 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

SEC source: 0001209191-22-056441 · doc4.xml · derivative · entry 2

SAUNDERS BRENT L · CIK 0001268854 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,647

Underlying: Common Stock · 153,647 shares

Expires 2031-06-15

F3 · price: Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F4 · price: Received in exchange for a stock option to acquire 130,000 shares of common stock of ARS with the exercise price of $1.19 per share pursuant to the Merger Agreement.

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056441 · doc4.xml · derivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 590,950

Underlying: Common Stock · 590,950 shares

Expires 2031-06-15

F2 · price: Received in exchange for a stock option to acquire 500,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $1.19 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement").

F3 · price: Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056440 · doc4.xml · derivative · entry 3

Kelly Michael · CIK 0001952533 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,190

Underlying: Common Stock · 118,190 shares

Expires 2031-12-13

F5 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F7 · price: Received in exchange for a stock option to acquire 100,000 shares of common stock of ARS pursuant to the Merger Agreement.

F6 · derivative.exercise_date: The shares vest in a series of thirty-six (36) successive equal monthly installments measured from the vesting commencement date.

SEC source: 0001209191-22-056440 · doc4.xml · derivative · entry 2

Kelly Michael · CIK 0001952533 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,422

Underlying: Common Stock · 70,422 shares

Expires 2029-07-04

F4 · price: Received in exchange for a stock option to acquire 59,584 shares of common stock of ARS pursuant to the Merger Agreement.

F5 · price: Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-056440 · doc4.xml · nonDerivative · entry 1

Kelly Michael · CIK 0001952533 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The 2019 Michael Kelly Irrevocable Deed of Trust

Disclosed balance after: 83,225

F1 · price: Received in exchange for 70,416 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F2 · ownership.nature: The Reporting Person's spouse and sister are trustees of the trust. The beneficiary of the trust is the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these Securities for purposes of Section 16 or for any other purpose.

SEC source: 0001209191-22-056439 · doc4.xml · nonDerivative · entry 1

Dadoo Rajeev · CIK 0001951685 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 2

Disclosed balance after: 3,009,677

F1 · price: Received in exchange for 2,546,473 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F2 · ownership.nature: The securities are directly held by SR One Capital Fund II Aggregator, LP ("SR One Fund II Aggregator"). SR One Capital Partners II, LP ("SR One Partners II") serves as the general partner of SR One Fund II Aggregator and SR One Capital Management, LLC serves as the general partner of SR One Partners II. The Reporting Person is the managing partner of SR One Capital Management, LP, an entity affiliated with SR One Fund II Aggregator, and a limited partner of SR One Partners II. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001209191-22-056438 · doc4.xml · derivative · entry 1

Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 827,330

Underlying: Common Stock · 827,330 shares

Expires 2032-03-01

F2 · price: Received in exchange for a stock option to acquire 700,000 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") with the exercise price of $1.77 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc.

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

SEC source: 0001209191-22-045023 · doc4.xml · derivative · entry 2

Shawver Laura · CIK 0001551891 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 402,997

Underlying: Common Stock · 78,740 shares

Expires 2030-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares vested on April 16, 2021 and the remaining shares shall vest in 36 equal monthly installments thereafter.